CN103189359A - 5-ht2c激动剂的光学活性酸盐 - Google Patents

5-ht2c激动剂的光学活性酸盐 Download PDF

Info

Publication number
CN103189359A
CN103189359A CN201180052813XA CN201180052813A CN103189359A CN 103189359 A CN103189359 A CN 103189359A CN 201180052813X A CN201180052813X A CN 201180052813XA CN 201180052813 A CN201180052813 A CN 201180052813A CN 103189359 A CN103189359 A CN 103189359A
Authority
CN
China
Prior art keywords
salt
weight
present
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180052813XA
Other languages
English (en)
Chinese (zh)
Inventor
A.C.布莱克本
W.L.贝茨三世
J.K.鲁特
单芸
A.西弗里纳
S.斯特恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN103189359A publication Critical patent/CN103189359A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180052813XA 2010-09-01 2011-08-31 5-ht2c激动剂的光学活性酸盐 Pending CN103189359A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40258010P 2010-09-01 2010-09-01
US61/402,580 2010-09-01
PCT/US2011/049935 WO2012030938A1 (en) 2010-09-01 2011-08-31 Salts of lorcaserin with optically active acids

Publications (1)

Publication Number Publication Date
CN103189359A true CN103189359A (zh) 2013-07-03

Family

ID=44653551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180052813XA Pending CN103189359A (zh) 2010-09-01 2011-08-31 5-ht2c激动剂的光学活性酸盐

Country Status (10)

Country Link
US (2) US9248133B2 (enExample)
EP (1) EP2611782A1 (enExample)
JP (1) JP2013539470A (enExample)
KR (1) KR20130138770A (enExample)
CN (1) CN103189359A (enExample)
AU (1) AU2011296014A1 (enExample)
CA (1) CA2808909A1 (enExample)
MX (1) MX2013002422A (enExample)
SG (2) SG188364A1 (enExample)
WO (1) WO2012030938A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
SG10201506874UA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
SG10201506865WA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
NZ630494A (en) 2010-09-01 2016-05-27 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
MY181736A (en) 2012-10-09 2021-01-05 Arena Pharm Inc Method of weight management
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN105431415A (zh) * 2013-05-20 2016-03-23 斯洛文尼亚莱柯制药股份有限公司 通过烯烃的弗瑞德-克来福特烷基化进行的8-氯-3-苯并[d]氮杂*的新合成方法
EP3010887A1 (en) 2013-06-21 2016-04-27 LEK Pharmaceuticals d.d. Preparation of chiral 1-methyl-2,3,4,5-1h-benzodiazepines via asymmetric reduction of alpha-substituted styrenes
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
EA022748B1 (ru) * 2014-06-02 2016-02-29 Делкростон Менеджмент Лимитед Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением
TW201618787A (zh) 2014-10-30 2016-06-01 艾尼納製藥公司 組合物及方法
JP6947406B2 (ja) 2015-08-21 2021-10-13 アルデイラ セラピューティクス， インコーポレイテッド 重水素化化合物およびその使用
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003096A1 (en) * 2003-06-17 2005-01-13 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
WO2005019179A2 (en) * 2003-06-17 2005-03-03 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
CN1646493A (zh) * 2002-04-12 2005-07-27 阿伦纳药品公司 5HT2c受体调节剂
WO2007120517A2 (en) * 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
CN101084193A (zh) * 2004-12-21 2007-12-05 艾尼纳制药公司 (r)－8－氯－1－甲基－2,3,4,5－四氢－1h－3－苯并氮杂卓盐酸盐的晶型
WO2008070111A2 (en) * 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2900415A (en) 1954-12-14 1959-08-18 Lakeside Lab Inc Synthesized antispasmodic compounds
CH498122A (de) 1968-02-09 1970-10-31 Geigy Ag J R Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
CH481110A (de) 1967-02-17 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
CH500194A (de) 1968-02-15 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von Tetrahydroazepinderivaten
US4233217A (en) 1968-03-11 1980-11-11 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
CA974989A (en) 1968-03-11 1975-09-23 Wallace And Tiernan Inc. Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby
FR314F (enExample) 1968-03-22 1970-05-25
FR7736M (enExample) 1968-09-02 1970-03-09
US3716639A (en) 1970-03-11 1973-02-13 Ciba Geigy Corp Anorexigenic tetrahydrobenzazepines
US3795683A (en) 1970-08-19 1974-03-05 Hoffmann La Roche 2,3,4,5-tetrahydro-1h-3-benzazepines
LU65954A1 (enExample) 1972-08-25 1974-03-07
US4210749A (en) 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
SE7510988L (sv) 1975-10-01 1977-04-02 Draco Ab Nya farmaceutiskt aktiva foreningar
US4111957A (en) 1977-02-02 1978-09-05 Smithkline Corporation Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4108989A (en) 1977-04-01 1978-08-22 Smithkline Corporation 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones
DE2758001A1 (de) 1977-12-24 1979-07-12 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
CA1090797A (en) 1978-06-20 1980-12-02 Kenneth G. Holden Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds
AU515236B2 (en) 1978-06-26 1981-03-26 Smithkline Corporation Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives
ZA792785B (en) 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
IE50355B1 (en) 1979-10-20 1986-04-02 Wyeth John & Brother Ltd Morpholine derivatives
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
DE3272044D1 (de) 1981-11-27 1986-08-21 Smithkline Beckman Corp 3-benzazepines as alpha-2 antagonists
ZA827887B (en) 1981-11-27 1983-11-30 Smithkline Beckman Corp Pharmaceutical compositions and method of producing alpha2 antagonism
FR2518544A1 (fr) 1981-12-22 1983-06-24 Lipha Benzodiazepines-1,3 thione-2, procede de preparation et medicament les contenant
FR2525603A1 (fr) 1982-04-27 1983-10-28 Adir Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4988690A (en) 1982-06-14 1991-01-29 Hoechst-Roussel Pharmaceuticals Inc. 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
DE3418270A1 (de) 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4541954A (en) 1984-09-05 1985-09-17 Smithkline Beckman Corporation Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB8610668D0 (en) 1986-05-01 1986-06-04 Pfizer Ltd Anti-arrhythmia agents
EG18188A (en) 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
US4762845A (en) 1986-05-21 1988-08-09 Abbott Laboratories 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US5015639A (en) 1987-03-27 1991-05-14 Schering Corporation Substituted benzazepines, their preparation and pharmaceutical compositions containing them
ZA882080B (en) 1987-03-27 1989-04-26 Schering Corp Substituted benzazepines,their preparation and pharmaceutical compositions containing them
US5247080A (en) 1987-03-27 1993-09-21 Schering Corporation Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds
AU1700688A (en) 1987-04-09 1988-11-04 Smithkline Beckman Corporation Sulfinyl and sulfonyl substituted 3-benzazepines
US4957914A (en) 1987-05-15 1990-09-18 Syntex (U.S.A.) Inc. 1,9-alkano-bridged-2,3,4,5-tetrahydro-1H-3-benzazepines
DK107688D0 (da) 1988-03-01 1988-03-01 Novo Industri As Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
US5178786A (en) 1989-08-04 1993-01-12 The Lubrizol Corporation Corrosion-inhibiting compositions and functional fluids containing same
JPH07119189B2 (ja) * 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
CA2037162A1 (en) 1990-03-12 1991-09-13 Steven Howard Shaber Heterocyclicacetonitriles and fungicidal use
WO1991019698A1 (en) 1990-06-15 1991-12-26 Schering Corporation 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them
US5275915A (en) 1991-06-05 1994-01-04 Dainippon Ink And Chemicals, Inc. Developer for light-sensitive material
PT100602A (pt) * 1991-06-21 1993-09-30 Smithkline Beecham Plc Uso de derivados de tetra-hidrobenzazepinas, derivados de tetra-hidrobenzazepinas,sua preparacao e composicoes farmaceuticas que os contem
GB9116824D0 (en) 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
EP0558824A1 (en) 1992-02-04 1993-09-08 Duphar International Research B.V Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
JPH06298746A (ja) 1993-04-19 1994-10-25 Showa Denko Kk 環状イミド酸エステルの製造法
US6087346A (en) 1993-06-23 2000-07-11 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
DE4419246A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419315A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419247A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4427838A1 (de) 1994-08-05 1996-02-08 Thomae Gmbh Dr K Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4429079A1 (de) 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH08134048A (ja) 1994-11-08 1996-05-28 Sumitomo Chem Co Ltd オキサゾリン類の製造法
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
JPH0930960A (ja) 1995-07-18 1997-02-04 Takasago Internatl Corp 真菌感染症治療剤
JPH0987258A (ja) 1995-09-28 1997-03-31 Sumitomo Chem Co Ltd オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
US5892116A (en) 1996-01-03 1999-04-06 Georgetown University Gelators
US5925651A (en) 1996-04-03 1999-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
WO1998006701A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
WO1998040385A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
AUPP020297A0 (en) 1997-11-05 1997-11-27 University Of Melbourne, The A novel receptor, and compounds which bind thereto
AU3275999A (en) 1998-03-10 1999-09-27 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
CA2325741C (en) 1998-03-26 2007-05-08 Santen Pharmaceutical Co., Ltd. Urea derivatives having tnf- .alpha. production inhibitory effects
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
EP0987235B1 (en) 1998-08-25 2003-03-12 MERCK PATENT GmbH Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1074549B1 (en) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
ES2209728T3 (es) 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.
JP2001076413A (ja) 1999-09-06 2001-03-23 Sony Corp フレキシブル磁気ディスク用ヘッドスライダー
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
DE10003708A1 (de) 2000-01-28 2001-08-02 Solvent Innovation Gmbh Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form
CZ300945B6 (cs) 2000-06-30 2009-09-23 Glaxo Group Limited Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu
CZ20031311A3 (cs) 2000-11-14 2004-04-14 Smithkline Beecham P. L. C. Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla)
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
JPWO2002074746A1 (ja) 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1425577A4 (en) * 2001-08-10 2004-12-29 Symyx Technologies Inc APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
MXPA04002785A (es) 2001-09-24 2004-07-29 Elan Pharm Inc Aminas sustituidas para tratamiento de enfermedad de alzheimer.
WO2003062205A1 (en) 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
WO2003057161A2 (en) 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20070179155A1 (en) 2003-06-20 2007-08-02 Brian Smith N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
TW200510324A (en) 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
US20070275949A1 (en) 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
WO2005042491A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
EP2479168B1 (en) * 2004-02-25 2014-04-09 Eli Lilly And Company 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists
SE0401871D0 (sv) 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
US20080269282A1 (en) 2004-08-02 2008-10-30 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
JPWO2006043710A1 (ja) 2004-10-19 2008-05-22 株式会社リバース・プロテオミクス研究所 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
KR101519441B1 (ko) * 2004-12-23 2015-05-12 아레나 파마슈티칼스, 인크. 5ｈｔ２ｃ 수용체 조정물질 조성물 및 그의 사용 방법
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
PT1924560E (pt) * 2005-09-01 2009-10-23 Lilly Co Eli 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c
BRPI0615033A2 (pt) * 2005-09-01 2011-04-26 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
RS52065B (sr) 2007-01-04 2012-06-30 Prosidion Ltd Piperidinski gpcr agonisti
EP2164324B1 (en) 2007-06-15 2014-08-13 University Of Florida Research Foundation Therapeutic compounds
EP2237781A2 (en) 2007-12-20 2010-10-13 NeuroSearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity
WO2009097416A1 (en) 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Imidazolylalkyl- pyridines as dbh inhibitors
WO2009111004A1 (en) 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
CL2009000782A1 (es) 2008-03-31 2010-04-30 Metabolex Inc Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
NZ588894A (en) * 2008-04-04 2012-12-21 Process for preparing (s)-pregabalin by chiral resolution
CA2726611A1 (en) * 2008-06-18 2009-12-23 Inspire Pharmaceuticals, Inc. Process for the preparation of rho-kinase inhibitor compounds
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
MX2013002430A (es) 2010-09-01 2013-07-22 Arena Pharm Inc Formas de dosis de disolucion de rápida de agonistas de 5-ht2c.
NZ630494A (en) 2010-09-01 2016-05-27 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
SG10201506874UA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
CN102126988A (zh) 2010-12-17 2011-07-20 张家港瀚康化工有限公司 4-(4-氯苯基)-2-溴甲基-2-苯基丁腈的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646493A (zh) * 2002-04-12 2005-07-27 阿伦纳药品公司 5HT2c受体调节剂
WO2005003096A1 (en) * 2003-06-17 2005-01-13 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
WO2005019179A2 (en) * 2003-06-17 2005-03-03 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
CN101084193A (zh) * 2004-12-21 2007-12-05 艾尼纳制药公司 (r)－8－氯－1－甲基－2,3,4,5－四氢－1h－3－苯并氮杂卓盐酸盐的晶型
WO2007120517A2 (en) * 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
WO2008070111A2 (en) * 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABU T.M.SERAJUDDIN: "Salt formation to improve drug solubility", 《ADVANCED DRUG DELIVERY REVIEWS》, vol. 59, no. 7, 24 August 2007 (2007-08-24), pages 603 - 616, XP022211982, DOI: doi:10.1016/j.addr.2007.05.010 *
STEPHEN BYRN等: "Pharmaceutical Solids:A Strategic Approach to Regulatory Considerations", 《PHARMACEUTICAL RESEARCH》, vol. 12, no. 7, 1 July 1995 (1995-07-01), pages 945 - 954, XP000996386, DOI: doi:10.1023/A:1016241927429 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途

Also Published As

Publication number Publication date
AU2011296014A1 (en) 2013-04-04
JP2013539470A (ja) 2013-10-24
US20160151381A1 (en) 2016-06-02
WO2012030938A1 (en) 2012-03-08
US9248133B2 (en) 2016-02-02
SG188364A1 (en) 2013-04-30
CA2808909A1 (en) 2012-03-08
US20130310369A1 (en) 2013-11-21
MX2013002422A (es) 2013-05-17
KR20130138770A (ko) 2013-12-19
SG10201506870PA (en) 2015-10-29
EP2611782A1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
CN103189359A (zh) 5-ht2c激动剂的光学活性酸盐
US10463676B2 (en) Modified-release dosage forms of 5-HT2C agonists useful for weight management
CN103189358A (zh) 5-ht2c激动剂的快速溶解剂型
US20170096398A1 (en) Non-hygroscopic salts of 5-ht2c agonists
AU2015268758A1 (en) Modified-release dosage forms of 5-HT2c agonists useful for weight management
HK1186985A (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
HK1186985B (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130703